Producer
Pfizer (Hospira / Pfizer Injectables)
Pfizer Inc. (New York NY; NYSE: PFE; ~$58B revenue 2023) is the largest seller of finished cisplatin and carboplatin injectable products in the US market, marketed under the Hospira brand (acquired 2015 for $17B). Pfizer's McPherson Kansas facility (formerly Hospira) is the primary US manufacturing site for cisplatin and carboplatin finished injectable vials. Pfizer sources cisplatin/carboplatin API primarily from Indian manufacturers, historically including Intas/Accord. When Intas shut down API production in late 2022, Pfizer was among the most directly affected finished-dose manufacturers and a primary party in FDA shortage communications. Pfizer's Hospira business is the largest US generic injectable manufacturer across multiple therapeutic categories.
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input Pfizer (Hospira / Pfizer Injectables) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Pfizer (Hospira / Pfizer Injectables) makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Generic Oncology Injectables (Hospira)
35%Hospital Specialty Injectables
30%Vaccines (Comirnaty, Prevnar, Nimenrix)
25%Specialty Biologics & Other
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Pfizer's McPherson, Kansas facility makes generic cisplatin and carboplatin (critical oncology chemotherapy supply chain) AND propofol (the universal general anesthesia agent for surgical procedures). When McPherson experienced quality issues in 2023-2024 that contributed to the US cisplatin shortage, it simultaneously affected: cancer treatment availability (oncology supply chain) AND surgical procedure capacity (since propofol backup supplies were also drawing from the same facility and personnel). The same factory producing chemotherapy for cancer patients is producing the anesthetic that allows surgeons to operate on those cancer patients — two entirely separate clinical supply chains sharing a single manufacturing facility, visible only to supply chain crisis analysts.
American Society of Health-System Pharmacists ↗Origin2015
The Hospira manufacturing assets at the center of Pfizer's generic injectable business trace to Abbott Laboratories' hospital products division — which in turn traces to Abbott's 1943 role in producing the first commercially manufactured injectable penicillin for WWII battlefield use. Abbott spun off Hospira in 2004 as the world's largest dedicated provider of injectable drugs and infusion systems. Pfizer acquired Hospira for $17 billion in 2015, integrating it with its own hospital and specialty injectable portfolio. The McPherson, Kansas manufacturing facility — the primary US source of generic cisplatin for chemotherapy — is the descendant of wartime pharmaceutical infrastructure built to defeat battlefield infections.
Pfizer Inc ↗